Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

Reduced hemorrhagic complications of intravenous glycoprotein IIb/IIIa inhibitors in flow diversion for ruptured aneurysms: A single-center study and meta-analysis. (PubMed, Interv Neuroradiol) - "We retrospectively reviewed rIA patients treated with FD at our institution.ResultsTwenty-six studies were included (387 patients): 167 (43.1%) received GPIIb/IIIa-only protocols and 220 (56.9%) received classic AP (predominantly aspirin and clopidogrel). Six received intra-procedural tirofiban, and one received ticagrelor/aspirin. Hemorrhagic and ischemic complications each occurred in 1/7 (14.3%) patients, two (28.6%) died and four (57.1%) achieved modified Rankin Scale ≤ 2 at 90 days.ConclusionsIV GPIIb/IIIa inhibitors administered at FD deployment for rIA are associated with fewer hemorrhagic complications without increased ischemic events and represent a feasible acute management strategy."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Viscoelastic coagulation testing in bleeding trauma patients: a retrospective analysis and development of a treatment algorithm. (PubMed, Br J Anaesth) - "These ClotPro® cut-off values allow for early and reliable detection of hypofibrinogenaemia and thrombocytopenia. Only after correction of fibrinogen and platelet deficits should prolonged CT be considered a weak marker for the augmentation of coagulation factors."

Journal • Retrospective data • Hematological Disorders • Thrombocytopenia

The efficacy and safety of tirofiban plus thrombolysis and thrombolysis alone for acute ischemic stroke: A meta-analysis. (PubMed, Am J Emerg Med) - "Tirofiban plus thrombolysis was associated with better functional outcomes, but not sICH, aICH, bleeding from other sites, or mortality among patients with AIS compared with thrombolysis only. Further studies should focus on its safety profile and application to target patients."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Vascular Neurology

The safety and efficacy of tirofiban therapy after intravenous thrombolysis in patients with acute ischemic stroke: A systematic review and meta-analysis. (PubMed, Clin Neurol Neurosurg) - "Tirofiban administration may be safe and effective in AIS patients, regardless of whether they undergo bridging therapy after intravenous thrombolysis. However, further randomized controlled clinical trials are warranted to validate these findings."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Denatured albumin is a potent ligand mediating platelet activaiton, adhesion and aggregation (ASH 2025) - "Inhibition of integrin αIIbβ3 (glycoprotein IIb/IIIa) using tirofiban or the 7E3 monoclonal antibodyabolished these force signals, identifying αIIbβ3 as the key receptor mediating platelet binding todenatured albumin...Using molecular engineering and platelet force imaging, we demonstrate that denatured albumin acts asa functional ligand for integrin αIIbβ3, promoting platelet activation, adhesion, and aggregation. Thisinteraction is mechanosensitive and specific to platelets.Given the high concentration of albumin in blood, even albumin denaturation at a low level, potentiallyinduced by oxidative stress, alcohol consumption, or pathological conditions such as diabetes, hepatitis,or sepsis, may have significant, previously unrecognized effects on platelet function and thrombotic risk.Our findings identify denatured albumin as a novel and strong regulator of platelet activity, opening newavenues in the understanding of thrombosis and hemostasis and therapeutic targeting..."

Cardiovascular • Diabetes • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • Septic Shock • Thrombosis • VCL

Medical and perioperative management of acute and subacute heparin-induced thrombocytopenia in adults requiring urgent cardiopulmonary bypass surgery. (ASH 2025) - "After diagnosis of HIT, most were started on the alternative anticoagulants argatroban or bivalirudin(bival) in 0-1 days...These cases(each n=1) were not grouped: IO heparin+tirofiban with pre-op PLEX+IVIG, IO heparin alone, IO heparinwith pre-op plus IO PLEX, and 1 who died before planned surgery...IO bival appears to increase risk of IO and post-op bleeding but conclusions are limited bysample size. Larger, comparative studies are needed to determine and characterize the optimalmanagement approach for this unique clinical scenario."

Clinical • Surgery • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Infectious Disease • Nephrology • Renal Disease • Thrombocytopenia • Thrombosis

Evaluation of the Efficacy and Safety of Tirofiban in the Treatment of Acute Ischemic Stroke with Non-large Vessel Occlusion beyond the Intravenous Thrombolysis Time Window (ChiCTR) - P=N/A | N=186 | Not yet recruiting | Sponsor: Bozhou People's Hospital; Bozhou People's Hospital

New trial • Cardiovascular • Ischemic stroke

Conservative Management of Non-Obstructive Left Main Coronary Artery Thrombus in the Setting of Myopericarditis (AHA 2025) - "We describe a case in which myopericarditis likely contributed to the formation of a non-obstructive left main coronary artery thrombus in the setting of overlapping systemic inflammation and underlying prothrombotic risk, managed conservatively without percutaneous intervention.Case presentation:A 36-year-old male with a history of well-controlled HIV on ART, presented with fever, hypotension, and a morbilliform rash shortly after initiation of trimethoprim-sulfamethoxazole for a skin and soft tissue infection...The patient was managed with a tirofiban bolus and infusion, a heparin drip, and dual antiplatelet therapy with aspirin and clopidogrel...In patients with non-obstructive coronary thrombus trigerred by a prothrombotic state, conservative management with anticoagulation and antiplatelet therapy may be appropriate in those who are hemodynamically stable. Clinicians should maintain a high index of suspicion for thrombotic complications in patients with systemic..."

Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Hypotension • Infectious Disease • Inflammation • Thrombosis

Tetrastigma hemsleyanum polysaccharides as natural inhibitors of platelet thrombosis via GPIIb/IIIa and MAPK pathways. (PubMed, Phytomedicine) - "THP5 exerts potent antithrombotic effects by directly targeting GPIIb/IIIa and modulating PKCα-MAPK-dependent platelet activation, supporting its potential as a safe and effective therapeutic candidate for thrombotic disorders."

Journal • Cardiovascular • Hematological Disorders • Inflammation • Thrombosis

USE OF TIROFIBAN IN ACUTE LARGE AND SMALL VESSEL OCCLUSION: A CASE SERIES (WSC 2025) - "Tirofiban IV was followed by enoxaparin ± clopidogrel, with stable outcomes. Tirofiban appears to be a safe and flexible option in acute ischemic stroke when MT is not performed or incomplete. It was well tolerated across various scenarios, including elderly, cardioembolic, and posterior circulation strokes. Further research is warranted to define optimal dosing, indications, and outcomes."

Clinical • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombosis

ACUTE INTRACRANIAL STENTING FOR PEDIATRIC STROKE DUE TO FOCAL CEREBRAL ARTERIOPATHY: A CASE REPORT (WSC 2025) - "After starting dual anti-platelet therapy, endovascular procedure was performed: a Solitaire AB 4x20mm stent-retriever was first deployed to debulk the lesion, followed by release of Pegasus 3.5x15mm stent and tirofiban intravenous infusion, achieving complete recanalization... The literature on intracranial stenting in pediatric patients is limited to a few case reports, primarily involving intracranial arterial dissection following failure of optimal medical management. In this case, an aggressive stenting approach proved both effective and safe. Continued clinical and radiological monitoring is warranted, given the limited data on the long-term outcomes in the pediatric population."

Case report • Clinical • Cardiovascular • CNS Disorders • Giant Cell Arteritis • Pediatrics • Vascular Neurology

PREOPERATIVE AND INTRAOPERATIVE TIROFIBAN PLUS ENDOVASCULAR TREATMENT IN PATIENTS WITH INTRACRANIAL ARTERY ATHEROSCLEROSIS: A META-ANALYSIS OF 3,393 PATIENTS (WSC 2025) - "Our findings suggest that intraoperative tirofiban has the potential to reduce mortality, risk of reocclusion at 90-day and favorable 90-day mRS in patients with LVO-A. Large multicentric clinical trials are necessary to determined what is the dosis of Tirofiban, the ideal via and the moment of administration."

Retrospective data • Atherosclerosis • Cardiovascular • Hematological Disorders • Ischemic stroke

OPTIMAL INTRAPROCEDURAL ANTIPLATELET STRATEGY DURING RESCUE STENTING FOR REFRACTORY LARGE VESSEL OCCLUSION: A SUB-STUDY OF THE RESISTANT REGISTRY (WSC 2025) - "Antiplatelet regimens were classified as intravenous (IV-APT) (cangrelor, tirofiban, eptifibatide, abciximab), single oral (aspirin, clopidogrel, ticagrelor), or dual oral therapy. ConclusionsIntraprocedural intravenous antiplatelet therapy was associated with improved procedural success and reduced re-occlusion without a significant impact on hemorrhagic or functional outcomes. These findings support the procedural safety of IV antiplatelets and highlight their potential benefit in optimizing reperfusion outcomes during rescue stenting."

Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT. (PubMed, Circulation) - P=N/A | "The use of tirofiban was permitted in both groups during and after the procedure...Among Chinese patients with large vessel occlusion with unsuccessful recanalization or high-grade residual stenosis after thrombectomy, BAOS was associated with reduced disability and stroke recurrence after 1 year compared with standard therapy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05122286."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders

The effect of remote ischemic conditioning combined with tirofiban on early neurological deterioration in small artery occlusive stroke. (PubMed, BMC Neurol) - "In patients with small artery occlusive stroke experiencing END, the combination of RIC and tirofiban seems associated with early neurological improvement without increasing the risk of intracranial hemorrhage or serious adverse events. Future multicenter, large-sample randomized clinical trials are warranted to validate these results."

Clinical • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Efficacy of Tirofiban combined with oral antiplatelet therapy in progressive ischemic stroke: A systematic review and meta-analysis. (PubMed, Exp Ther Med) - "The study was conducted according to the preferred reporting items for systematic reviews and meta-analyses guidelines and registered with PROSPERO (no. CRD42025633357), and the findings suggested that tirofiban-augmented antiplatelet regimens safely improve clinical outcomes in progressive cerebral infarction, particularly when combined with dual oral antiplatelet agents."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Intravenous Tirofiban Following Endovascular Therapy for Patients with Acute Large Vessel Occlusion Stroke. (PubMed, Int J Stroke) - "No significant differences were found in sICH, END, or 90-day mortality between groups across all cohorts.ConclusionIV tirofiban administration following EVT was associated with improved favorable functional outcomes in AIS patients with anterior-circulation LVO, without increasing the risk of sICH or END, but no significant association was observed in PCS patients. Further randomized controlled trials are warranted to verify these findings."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

ANGEL-DRUG: Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke (clinicaltrials.gov) - P=N/A | N=716 | Recruiting | Sponsor: Beijing Anzhen Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Atherosclerosis • Cardiovascular • Ischemic stroke

A commentary on "association of functional outcomes between intravenous tirofiban and endovascular thrombectomy in imaging-screened patients with large vessel occlusion stroke: a secondary analysis of randomized clinical trial". (PubMed, Int J Surg) - No abstract available

Clinical • Journal • Cardiovascular

The inhibitory effect of antiplatelet drugs on spontaneous platelet aggregation on glass surfaces: an analysis based on microscopic three-dimensional topography. (PubMed, J Thromb Thrombolysis) - "Ticagrelor, eptifibatide, and tirofiban dose-dependently decreased both Vol and CS-area...GPIb-IX-von Willebrand factor (vWF) inhibitors (4 μM) and indomethacin (4 μM) significantly reduced both Vol and CS-area, with a smaller reduction in CS-area compared to Vol. In patients, aspirin alone significantly reduced Vol, while clopidogrel, aspirin combined with clopidogrel, and Xuesaitong significantly decreased both Vol and CS-area. Our novel analytical strategy is capable of distinguishing the pharmacological effects of various antiplatelet agents without the need for exogenous agonists, suggesting that this system may aid in the determination of the appropriate type and dose of the antiplatelet agent in the clinical setting."

Journal

Serum Lipid Profiles as Predictors of Hemorrhagic Transformation After Thrombolysis in Acute Cerebral Infarction: A Prospective Study. (PubMed, Curr Neurovasc Res) - "Patients with ACI undergoing IVT who had higher baseline NIHSS scores, lower TC, higher HDL, and a higher T/H ratio were at increased risk of HT, which was also associated with long-term outcomes. The T/H ratio may be a valuable predictor of HT following IVT."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Hypertension

A disproportionality analysis of real-world adverse events associated with tirofiban from the FAERS database. (PubMed, Sci Rep) - "Furthermore, other relatively rare but statistically significant AEs were identified, including acute respiratory failure, hemolysis, prolonged activated partial thromboplastin time (APTT), coagulopathy, and disseminated intravascular coagulation (DIC). The temporal analysis showed the median onset time of AEs was 1 day, which urges immediate monitoring after drug administration, such as symptom surveillance and complete blood count evaluation."

Adverse events • Journal • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Ischemic stroke • Respiratory Diseases • Thrombocytopenia • Thrombosis

ATTRACTION: Tirofiban After Successful MT Recanalization in AIS (clinicaltrials.gov) - P2/3 | N=1360 | Recruiting | Sponsor: Xiang Luo | Trial completion date: Sep 2027 ➔ Jan 2026 | Trial primary completion date: Mar 2027 ➔ Jan 2026

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Effects of intracoronary tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention [WITHDRAWN] (ESC-WCC 2025) - "The use of intracoronary Tirofiban in the setting of CNR in STEMI patients undergoing PPCI may be beneficial in the improvement of TIMI flow and myocardial blush grade with no benefit noted regarding in-hospital MACE and mortality."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Thrombosis

Tirofiban-induced acute profound thrombocytopenia in endovascular therapy for acute ischemic stroke: a rare case report. (PubMed, BMC Neurol) - No abstract available

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombocytopenia • Vascular Neurology